Loading
A phase 1 trial of YL211 alone in advanced solid tumours and with pembrolizumab in non-squamous non-small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06384352 by MediLink Therapeutics (Suzhou) Co., Ltd., with Hoffmann-La Roche as collaborator; 500 participants are planned, it started on 2024-05-01; the registry gives 2031-06-30 as its primary completion date. Interventions recorded: YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin). Conditions listed: Advanced Solid Tumors. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/